Biologics, including mepolizumab, benralizumab, and dupilumab, targeting cytokines IL-5, and IL-4/IL-13, respectively, have shown promising effects, leading to the reduction in annualized asthma exacerbation rates (AER), oral corticosteroid-sparing effects and improved Asthma Control Questionnaire scores (14, 15). This evidence concerns the gene IL13 and asthma.